RESULTS

The SHRINK study evaluates the autologous CYAD-01 with prior FOLFOX in advanced metastatic colorectal cancer patients. This combination has been found to have a favorable safety profile at all doses evaluated with no dose-limiting toxicities reported. No cumulative toxicities were noted upon multiple administrations of CYAD-01 with concurrent FOLFOX treatment. Based upon this safety profile, a dose of 1x10^7 CYAD-01 treatment is considered safe for further studies combining with FOLFOX chemotherapy. We await further information from tumor analysis collected from patients undergoing surgery in the non-adjuvant group. Given the small sample size of the populations in this dose-escalation study, it is not possible to dissect the contribution of CYAD-01 and FOLFOX to clinical responses. However, in the refractory setting, achieving SD in patients who previously received oxaliplatin-based therapies FOLFOX (3/4 patients) and FOLFIRI (4/4 patients) provides encouragement for the therapeutic combination of CYAD-01 and FOLFOX.

The results from this study will be compared to its sister study evaluating the allogeneic analog of CYAD-01 in mCRC that combine to support the development of CAR T-cell therapy in solid tumors (poster 339).

ACKNOWLEDGEMENTS & DISCLOSURES

Celyad thanks patients & their families, physicians, and study sites for all their support.

This study was funded and sponsored by Celyad SA (ClinicalTrials.gov identifier: NCT03135008).

LS, AH, AC, JC, JEC, JD, JPHM and MVDE are Investigators on the SHRINK study. EAO, FR, EC, CL and AF are employed by Celyad SA.

This poster is published for information only. The views expressed are those of the authors and not necessarily those of the organizations named herein.

Poster 331